A randomized controlled trial of radiofrequency ablation with ethanol injection for small hepatocellular carcinoma.

By S. Shiina, T. Teratani, S. Obi, Shin'pei Sato, R. Tateishi, T. Fujishima, T. Ishikawa, Y. Koike, H. Yoshida, T. Kawabe and 1 more. Gastroenterology, 2005

867 citations recorded by the source corpus.

Subfields: Genetics, Hepatology, Surgery

View Paper: https://www.semanticscholar.org/paper/80fe39c28defc899eab37d36d515d18041dfeb27

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Hepatology

1. J. Llovet
2. Jordi Bruix1 , 2
3. Alejandro Forner1 , 2
4. María E. Reig1 , 2
5. M. Kudo
6. Carlos Rodriguez de Lope1
7. A. Cheng
8. M. Sherman

In Surgery

1. Jordi Bruix1 , 2
2. J. Llovet

Citations in the corpus

• Current Strategy for Staging and Treatment: The BCLC Update and Future Prospects (2010, background): “Ablation has a marked decrease in efficacy when tumor size exceeds 3 cm and when more than 2 nodules are targeted.(39,65,78,79,88,89) Current data with both options indicate a 5 year survival of 70% at 5 years in patients with well preserved liver function, but as previously commented, if portal hyp”
• Asian Pacific Association for the Study of the Liver consensus recommendations on hepatocellular carcinoma (2010, background): “RFA is superior to ethanol injection in the treatment of small HCCs in terms of treatment response, recurrence, and overall survival [294–297], while some investigators reported that RFA had higher complication rates [295, 297].”
• Novel advancements in the management of hepatocellular carcinoma in 2008. (2008, background): “RF [94–97].”